It seems, that precutaneous replacements and repairs are really kicking off. Here is a report on first percutaneous repair of tricuspid valve:
Mitralign has reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation. The German regulatory body BfArM allowed the first-in-man procedure, which involves the percutaneous bicuspidisation of the tricuspid valve, to be performed under a compassionate use exemption because no other options were available for the patient who underwent the new procedure. According to a company press release, the procedure successfully converted a regurgitating tri-leaflet valve into a functioning bi-leaflet valve and was performed at the Albertinen Heart Center in Hamburg, Germany. The Mitralign product is currently being evaluated in clinical trials for an indication in functional mitral regurgitation. The device is not approved for sale or distribution.
See more at: http://www.cxvascular.com/cn-latest...ricuspid-valve-performed#sthash.MHGcF5ZQ.dpuf
Mitralign has reported on the successful use of its technology to perform a percutaneous repair on a patient with tricuspid regurgitation. The German regulatory body BfArM allowed the first-in-man procedure, which involves the percutaneous bicuspidisation of the tricuspid valve, to be performed under a compassionate use exemption because no other options were available for the patient who underwent the new procedure. According to a company press release, the procedure successfully converted a regurgitating tri-leaflet valve into a functioning bi-leaflet valve and was performed at the Albertinen Heart Center in Hamburg, Germany. The Mitralign product is currently being evaluated in clinical trials for an indication in functional mitral regurgitation. The device is not approved for sale or distribution.
See more at: http://www.cxvascular.com/cn-latest...ricuspid-valve-performed#sthash.MHGcF5ZQ.dpuf
